SPX4,305.36+8.22 0.19%
DIA341.71+2.34 0.69%
IXIC13,100.20-27.85 -0.21%

Alnylam Pharmaceuticals Q2 EPS $(2.03) Misses $(1.62) Estimate, Sales $224.82M Miss $255.88M Estimate

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported quarterly losses of $(2.03) per share which missed the analyst consensus estimate of $(1.62) by 25.31 percent. This is a 56.15 percent decrease over losses of $(1.30) per

Benzinga · 07/28/2022 08:05
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported quarterly losses of $(2.03) per share which missed the analyst consensus estimate of $(1.62) by 25.31 percent. This is a 56.15 percent decrease over losses of $(1.30) per share from the same period last year. The company reported quarterly sales of $224.82 million which missed the analyst consensus estimate of $255.88 million by 12.14 percent. This is a 1.93 percent increase over sales of $220.55 million the same period last year.